The US is preparing to impose an additional 7.5% tariff on Chinese goods, Watcher.Guru reported, citing Bloomberg. The move would push Trump-era duties on Chinese imports back up toward roughly 20% — a level Beijing has previously said would still be consistent with its existing trade truce with Washington, according to Bloomberg's original reporting.
The stated justification is overcapacity: US officials have pointed to Chinese manufacturing output that exceeds domestic and even global demand in sectors like steel, solar equipment and EVs, arguing the resulting excess supply gets dumped into export markets at prices domestic producers elsewhere can't match. Framing the new tariff specifically around overcapacity, rather than the broader trade-deficit language the administration has used before, signals officials are trying to make the measure legible as a targeted anti-dumping tool rather than a fresh escalation of the wider trade fight.
Timed Ahead of a Direct Trump-Xi Meeting
The timing is deliberate. Trump and Xi Jinping are due to meet in Washington on September 24, and the tariff move is being unveiled roughly a month ahead of that summit — a sequencing that suggests Washington wants added leverage on the table before the two leaders sit down, rather than springing a new measure on Beijing after talks conclude.
Related: China's Hidden Gold Buying Nearly Triples Official June Total
What It Means for the Trade Truce
Beijing has previously signaled it would treat roughly 20% as within the bounds of the existing truce framework it negotiated with Washington earlier in Trump's second term, which is the detail markets are likely to focus on: whether this specific increase falls inside or outside that understanding will determine whether China responds with retaliatory measures of its own or absorbs the increase as expected friction ahead of the summit. A truce that holds despite this increase would be a modestly bullish signal for risk assets broadly; a Chinese retaliatory response would suggest the September summit carries more downside risk than currently priced in.
